Conversation with VelaFi: How to Apply Stablecoins in Latin America?About 60% to 70% of people in Latin America still don’t have a bank account, and most are still using cash. For businesses or individuals operating there, if they can’t ensure the stability of the currency they hold, they face significant losses. when people receive payments in stablecoins, they begin to understand what stablecoins are and start holding them. Another reason is to avoid the losses caused by fluctuations in local currencies, ...

Ermenegildo Zegna (NYSE:ZGN) Q3 2025 Earnings Call October 23, 2025 07:00 AM ET Speaker4Hello everyone, and thank you for standing by. The Ermenegildo Zegna Group Q3 2025 revenue call will be beginning in just a few minutes' time. We thank you for your patience, and we will begin shortly. Good afternoon, good morning everyone. Thank you for joining the Ermenegildo Zegna Group Q3 2025 revenues call. Please note that today's material and presentation are available under the zegnagroup.com website. Joining us ...

Presentation[Interpreted] Ladies and gentlemen, welcome to the Q3 Analyst Conference for Hermès International. I now give the floor to Eric du Halgouët, CFO; and Antoine Riou, Head of Investor Relations. Gentlemen, over to you.Eric du HalgouëtExecutive Vice President of Finance [Interpreted] Thank you very much. Good morning, one and all. Thank you very much for joining us. In the third quarter, sales continued to grow and reached EUR 3.9 billion, up 10% at constant exchange rate, a slight improvement compa ...

Core Viewpoint - Abbott Laboratories is experiencing strong sales recovery in its Nutrition business, particularly driven by Ensure, and is well-positioned for growth in emerging markets and its Diabetes Care segment through the FreeStyle Libre system [1][5][6] Group 1: Sales Performance - Abbott's shares have increased by 19.6% over the past year, outperforming the industry growth of 9.1% and the S&P 500's increase of 5.4% [2] - In the fourth quarter of 2024, Abbott's Diabetes Care sales exceeded $1.8 billion, reflecting a 23% growth, while full-year sales reached approximately $6.5 billion, up 22% from 2023 [7] - The Nutrition business reported 7.1% organic growth in the fourth quarter of 2024, with Adult Nutrition growing by 11.4% [9] Group 2: Business Segments - The EPD (Established Pharmaceutical Division) is set for sustainable growth, with a five-year compound annual growth rate (CAGR) of 8% [3] - EPD sales in the fourth quarter of 2024 increased by 8.5% organically, with balanced growth across various therapeutic areas [4] - The FreeStyle Libre system has achieved global leadership in continuous glucose monitoring for both Type 1 and Type 2 diabetes users [5] Group 3: Market Dynamics - Abbott has gained momentum in the Diabetes Care segment with recent FDA approvals for new over-the-counter CGM systems, expanding its market reach [6] - The Nutrition business is expanding due to strong global demand for adult nutrition products, despite some softness in pediatric product markets [8] - Foreign exchange fluctuations have negatively impacted Abbott's sales, with a 1.4% unfavorable year-over-year effect noted in the fourth quarter of 2024 [10] Group 4: Financial Estimates - The Zacks Consensus Estimate for Abbott's 2025 earnings per share remains at $5.15, while revenues are projected to rise by 5.7% to $44.35 billion [11]